PAHC

+ Watchlist + Portfolio

Phibro Animal Health Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $35.44
52-Week Range: $28.25 – $60.08
Market Cap: $1.43B
P/E (TTM): 15.10
EPS (TTM): 2.33
Dividend Yield: 1.35%

Advanced Metrics

Price/Book: 3.94
PEG Ratio: 1.68
Return on Equity: 30.34%
Return on Assets: 8.40%
Gross Margin: 32.57%
Operating Margin: 12.56%
Profit Margin: 6.35%
Current Ratio: 3.17
Debt/Equity: 2.18
Total Debt: $788.68M
Free Cash Flow: $-17.68M
Revenue Growth: 10.30%
Earnings Growth: 15.70%
Enterprise Value: $2.15B

PAHC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$942.26M	$977.89M	$1.02B	$1.30B
Cost of Revenue	$656.86M	$679.65M	$704.59M	$896.27M
Gross Profit	$285.40M	$298.24M	$313.09M	$399.94M
Selling, General & Admin	$206.41M	$226.39M	$259.78M	$289.48M
Operating Expenses	$206.41M	$226.39M	$259.78M	$289.48M
Operating Income	$78.99M	$71.85M	$53.31M	$110.47M
EBITDA	$117.13M	$106.03M	$69.06M	$146.85M
Pretax Income	$72.33M	$54.07M	$10.92M	$67.99M
Income Tax	$23.15M	$21.46M	$8.50M	$19.73M
Net Income	$49.17M	$32.61M	$2.42M	$48.26M
Diluted EPS	1.21	0.81	0.06	1.19
Diluted Shares	40.50M	40.50M	40.52M	40.70M

PAHC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$74.25M	$41.28M	$70.61M	$68.04M
Receivables	$166.54M	$163.48M	$169.45M	$227.98M
Inventory	$259.16M	$277.57M	$265.91M	$444.43M
Current Assets	$566.23M	$585.72M	$601.00M	$810.61M
Total Assets	$931.70M	$971.40M	$982.18M	$1.36B
Current Liabilities	$190.83M	$176.00M	$204.15M	$293.47M
Long-Term Debt	$417.93M	$452.54M	$458.29M	$702.43M
Total Debt	$470.48M	$509.97M	$525.46M	$761.55M
Total Liabilities	$669.26M	$688.89M	$725.54M	$1.08B
Retained Earnings	$247.75M	$260.91M	$243.89M	$272.70M
Shareholders' Equity	$262.44M	$282.51M	$256.64M	$285.68M
Working Capital	$375.40M	$409.72M	$396.85M	$517.13M
Net Debt	$358.68M	$433.56M	$417.47M	$650.65M

PAHC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$31.65M	$13.31M	$87.59M	$80.12M
Capital Expenditure	-$37.04M	-$51.79M	-$41.24M	-$38.29M
Free Cash Flow	-$5.39M	-$38.48M	$46.36M	$41.83M
Depreciation & Amortisation	$32.70M	$34.01M	$36.18M	$45.60M
Stock-Based Compensation	$0.00	$0.00	$475.00K	$717.00K
Investing Cash Flow	-$22.58M	-$74.02M	-$48.19M	-$288.69M
Financing Cash Flow	$16.34M	$26.99M	-$6.77M	$207.13M
Dividends Paid	-$19.44M	-$19.44M	-$19.44M	-$19.45M
Net Change in Cash	$25.41M	-$33.72M	$32.63M	-$1.43M

PAHC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$347.82M	$378.70M	$363.89M	$373.91M	$383.54M
Cost of Revenue	$243.26M	$268.69M	$244.11M	$241.25M	$257.87M
Gross Profit	$104.57M	$110.01M	$119.78M	$132.66M	$125.67M
Selling, General & Admin	$71.05M	$76.29M	$68.52M	$82.33M	$81.02M
Operating Expenses	$71.05M	$76.29M	$68.52M	$82.33M	$81.02M
Operating Income	$33.52M	$33.72M	$51.26M	$50.33M	$44.65M
EBITDA	$51.38M	$44.71M	$61.07M	$61.16M	$54.87M
Pretax Income	$29.69M	$23.85M	$36.27M	$36.42M	$32.31M
Income Tax	$8.81M	$6.62M	$9.74M	$8.97M	$8.29M
Net Income	$20.88M	$17.22M	$26.53M	$27.46M	$24.02M
Diluted EPS	0.51	0.42	0.65	0.67	0.59
Diluted Shares	40.70M	40.70M	40.88M	40.96M	41.04M

PAHC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$60.35M	$68.04M	$72.77M	$55.49M	$54.93M
Receivables	$197.52M	$227.98M	$217.90M	$215.87M	$221.55M
Inventory	$448.39M	$444.43M	$471.77M	$517.35M	$539.70M
Current Assets	$776.02M	$810.61M	$835.80M	$862.18M	$894.07M
Total Assets	$1.32B	$1.36B	$1.39B	$1.41B	$1.45B
Current Liabilities	$266.48M	$293.47M	$270.14M	$282.37M	$281.87M
Long-Term Debt	$711.16M	$702.43M	$724.52M	$710.60M	$712.68M
Total Debt	$770.02M	$761.55M	$785.10M	$773.17M	$787.44M
Total Liabilities	$1.05B	$1.08B	$1.07B	$1.07B	$1.08B
Retained Earnings	$260.34M	$272.70M	$294.36M	$316.96M	$336.12M
Shareholders' Equity	$265.99M	$285.68M	$311.68M	$332.36M	$361.83M
Working Capital	$509.54M	$517.13M	$565.66M	$579.82M	$612.20M
Net Debt	$667.05M	$650.65M	$670.19M	$675.75M	$680.59M

PAHC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$43.15M	$21.27M	$9.30M	$19.35M	$16.21M
Capital Expenditure	-$7.75M	-$13.14M	-$13.81M	-$11.10M	-$15.32M
Free Cash Flow	$35.41M	$8.13M	-$4.50M	$8.26M	$890.00K
Depreciation & Amortisation	$12.62M	$12.41M	$12.83M	$12.89M	$12.45M
Stock-Based Compensation	$179.00K	$179.00K	$339.00K	$434.00K	$411.00K
Investing Cash Flow	-$18.25M	-$7.03M	-$21.01M	-$17.18M	-$16.81M
Financing Cash Flow	-$32.22M	-$7.77M	$16.34M	-$18.98M	-$2.30M
Dividends Paid	-$4.87M	-$4.86M	-$4.86M	-$4.86M	-$4.87M
Net Change in Cash	-$7.32M	$6.47M	$4.62M	-$16.81M	-$2.90M

Market Snapshot

About

Phibro Animal Health develops, manufactures, and markets animal health products including vaccines, antibiotics, nutritional supplements, and mineral nutrition ingredients. The company serves poultry, swine, dairy, and beef producers globally. Its products help improve animal health, nutrition, and production efficiency in livestock operations.